Insight into Biosimilars: Short Description, Analytical Assessment and Market

Main Article Content

Klaus Zimmermann Markus Fido Markus Roucka


The World Health Organization (WHO) defines a similar biotherapeutic product, i.e. a biosimilar as a biotherapeutic product that is similar in terms of quality, safety and efficacy to an already licensed reference product on the market (termed as originator or innovator). To ensure similar efficacy and safety, comparability studies for biosimilars should be carried out at quality, preclinical and clinical level.Glycosylation profiles of biosimilars are getting an additional critical quality attribute. The portfolio required for regulatory comparison of identity and release testing has to be assessed with a large number of analytical tests, which are presented here in detail for the example of adalimumab.Adalimumab, as one of the blockbuster drugs and the best-sellingpharmaceutical product world-wide, is analyzed additionally with a competitive field presenting the marketed products or such in development. This competitive field is not surprisingly very crowded. Furthermore, general information about the currently marketed biosimilars includingModeofAction (MoA), clinical indication(s), patent situation, and market situation are shortly summarized for each of the respective originator/biosimilar molecules.As there are not only markets in developed and highly regulated countries, but also in other regions, examples for companies and products in Asia, South and Middle America, and even in Africa are highlighted as well.

Article Details

How to Cite
ZIMMERMANN, Klaus; FIDO, Markus; ROUCKA, Markus. Insight into Biosimilars: Short Description, Analytical Assessment and Market. Medical Research Archives, [S.l.], v. 8, n. 3, mar. 2020. ISSN 2375-1924. Available at: <>. Date accessed: 22 feb. 2024. doi:
Research Articles


1. Kang H-N, Knezevic I. Regulatory evaluation of biosimilars throughout their product life-cycle. Bulletin of the World Health Organization 2018;96:281-285. doi:

2. de Mora F. Biosimilar: what it is not. Br J Clin Pharmacol. 2015 Nov; 80(5):949–956. Published online 2015 Jun 4. doi: 10.1111/bcp.12656

3. Araujo FC, Gonçalves J, Fonseca JE. Biosimilars in Rheumatology. Pharmacol Res. 2019 Sep 27;104467. doi: 10.1016/j.phrs.2019.104467.

4. Peyrin-Biroulet L, Danese S, Cummings F, et al. Anti-TNF biosimilars in Crohn's Disease: a patient-centric interdisciplinary approach. Expert Rev Gastroenterol Hepatol. 2019 Aug;13(8):731-738. doi: 10.1080/17474124.2019.1645595.

5. Vasudevan A, Gibson PR, Van Langenberg DR. Systematic Review: Cost-effective Strategies of Optimizing Anti-tumor Necrosis and Immunomodulators in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019 Aug 20;25(9):1462-1473. doi: 10.1093/ibd/izy399.

6. Barker J, Girolomoni G, Egeberg A, et al. Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience. J Dermatolog Treat. 2019 May 16:1-7. doi: 10.1080/09546634.2019.1610553.

7. Krendyukov A, Schiestl M. Biosimilars in oncology: A decade of experience with granulocyte colony-stimulating factor and its implications for monoclonal antibodies. Crit Rev Oncol Hematol. 2019 Jul 23. pii: S1040-8428(18)30307-X. doi: 10.1016/j.critrevonc.2019.07.009.

8. Barbier L, Declerck P, Simoens S, et al. The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars. Br J Cancer. 2019 Jul;121(3):199-210. doi: 10.1038/s41416-019-0480-z.

9. Migliavacca Zucchetti B, Nicolò E, Curigliano G. Biosimilars for breast cancer. Expert Opin Biol Ther. 2019 Jul 10:1-7. doi: 10.1080/14712598.2019.1638362.

10. Constantin MM, Cristea CM, Taranu T, et al. Biosimilars in dermatology: The wind of change. Exp Ther Med. 2019 Aug;18(2):911-915. doi: 10.3892/etm.2019.7505.

11. EMEA, Committee for Medicinal Products for Human Use (CHMP). Guideline on development, production, characterisation and specifications for monoclonal antibodies and related substances. 2008. CHMP/BWP/157653/2007.

12. EMEA, Committee for Medicinal Products for Human Use (CHMP). Guideline on similar biological medicinal products containing monoclonal antibodies – non-clinical and clinical issues. 2012. CHMP/BMWP/403543/201030.

13. EMEA, Committee for Medicinal Products for Human Use (CHMP). Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2014. CHMP/BMWP/42832/2005 Rev1.

14. Tsiftsoglou AS, Ruiz S, Schneider CK. Development and regulation of biosimilars: current status and future challenges. BioDrugs. 2013;27(3):203-11. doi: 10.1007/s40259-013-0020-y.

15. Chow SC, Song F, Bai H. Analytical Similarity Assessment in Biosimilar Studies. AAPS J. 2016;18(3):670-7. doi: 10.1208/s12248-016-9882-5.

16. FDA homepage. October 2017.

17. Chugh PK, Roy V. Biosimilars: current scientific and regulatory considerations. Curr Clin Pharmacol. 2014;9(1):53-63.

18. Wolff-Holz E, Tiitso K, Vleminckx C, Weise M. Evolution of the EU Biosimilar Framework: Past and Future. BioDrugs. 2019 Dec;33(6):621-634. doi: 10.1007/s40259-019-00377-y.

19. Kabir ER, Moreino SS, Sharif Siam MK. The Breakthrough of Biosimilars: A Twist in the Narrative of Biological Therapy. Biomolecules. 2019 Aug 24;9(9). pii: E410. doi: 10.3390/biom9090410.

20. Goldberg KB, Blumenthal GM, Pazdur R. The First Year of the Food and Drug Administration Oncology Center of Excellence: Landmark Approvals in a Dynamic Regulatory Environment. Cancer J. 2018 May/Jun;24(3):131-135. doi: 10.1097/PPO.0000000000000316.

21. Epstein M. Food and Drug Administration guidances on biosimilars: an update for the gastroenterologist. Therap Adv Gastroenterol. 2018 Oct 3;11:1756284818799600. doi: 10.1177/1756284818799600. eCollection 2018.

22. Pipalava P, Patel R, Mehta M, et al. An update on the animal studies conducted for biosimilar approvals - Regulatory requirement vs actual scenario. Regul Toxicol Pharmacol. 2019 Oct;107:104415. doi: 10.1016/j.yrtph.2019.104415.

23. Ishii-Watabe A, Kuwabara T. Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies. Drug Metab Pharmacokinet. 2019 Feb;34(1):64-70. doi: 10.1016/j.dmpk.2018.11.004.

24. Vandekerckhove K, Seidl A, Gutka H, et al. Rational Selection, Criticality Assessment, and Tiering of Quality Attributes and Test Methods for Analytical Similarity Evaluation of Biosimilars. AAPS J. 2018 May 10;20(4):68. doi: 10.1208/s12248-018-0230-9.

25. Zeng D, Pan J, Hu K, et al. Improving the power to establish clinical similarity in a Phase 3 efficacy trial by incorporating prior evidence of analytical and pharmacokinetic similarity. J Biopharm Stat. 2018;28(2):320-332. doi: 10.1080/10543406.2017.1397012.

26. Burdick R, Coffey T, Gutka H, et al. Statistical Approaches to Assess Biosimilarity from Analytical Data. AAPS J. 2017 Jan;19(1):4-14. doi: 10.1208/s12248-016-9968-0.

27. McClellan JE, Conlon HD, Bolt MW, et al. The 'totality-of-the-evidence' approach in the development of PF-06438179/GP1111, an infliximab biosimilar, and in support of its use in all indications of the reference product. Therap Adv Gastroenterol. 2019 Jun 13;12:1756284819852535. doi: 10.1177/1756284819852535. eCollection 2019.

28. Hong J, Lee Y, Lee C, et al. Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab). MAbs. 2017 Feb/Mar;9(2):364-382. doi: 10.1080/19420862.2016.1264550.

29. Jung SK, Lee KH, Jeon JW, et al. Physicochemical characterization of Remsima. MAbs. 2014;6(5):1163-1177. doi: 10.4161/mabs.32221.

30. Pisupati K, Tian Y, Okbazghi S, et al. A Multidimensional Analytical Comparison of Remicade and the Biosimilar Remsima. Anal Chem. 2017 May 2;89(9):4838-4846. doi: 10.1021/acs.analchem.6b04436.

31. Hermosilla J, Sánchez-Martín R, Pérez-Robles R, et al. Comparative Stability Studies of Different Infliximab and Biosimilar CT-P13 Clinical Solutions by Combined Use of Physicochemical Analytical Techniques and Enzyme-Linked Immunosorbent Assay (ELISA). BioDrugs. 2019 Apr;33(2):193-205. doi: 10.1007/s40259-019-00342-9.

32. Xu Y, Xie L, Zhang E, et al. Physicochemical and functional assessments demonstrating analytical similarity between rituximab biosimilar HLX01 and the MabThera®. MAbs. 2019 Apr;11(3):606-620. doi: 10.1080/19420862.2019.1578147.

33. Montacir O, Montacir H, Eravci M, et al. Comparability study of Rituximab originator and follow-on biopharmaceutical. J Pharm Biomed Anal. 2017 Jun 5;140:239-251. doi: 10.1016/j.jpba.2017.03.029.

34. Seo N, Polozova A, Zhang M, et al. Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab. MAbs. 2018 May/Jun;10(4):678-691. doi: 10.1080/19420862.2018.1452580.

35. Orlik G, Khan MA, Grieb P. Analytical Comparison of the Originator Granulocyte-colony Stimulating Factor Filgrastim and its Biosimilars. Curr Pharm Des. 2018;24(30):3543-3550. doi: 10.2174/1381612824666181109163118.

36. Mantovani M, Caruso C, Facchini F, et al. Physicochemical and biological comparison of the first Brazilian biosimilar filgrastim with its reference product. Biosimilars, August 2016; Volume 2016;6:45-60. DOI

37. Shekhawat R, Shah CK, Patel A, et al. Structural similarity, characterization of Poly Ethylene Glycol linkage and identification of product related variants in biosimilar pegfilgrastim. PLoS One. 2019 Mar 13;14(3):e0212622. doi: 10.1371/journal.pone.0212622. eCollection 2019.

38. Brokx S, Scrocchi L, Shah N, Dowd J. A demonstration of analytical similarity comparing a proposed biosimilar pegfilgrastim and reference pegfilgrastim. Biologicals. 2017 Jul;48:28-38. doi: 10.1016/j.biologicals.2017.06.001.

39. Miao S, Fan L, Zhao L, et al. Physicochemical and Biological Characterization of the Proposed Biosimilar Tocilizumab. Biomed Res Int. 2017;2017:4926168. doi: 10.1155/2017/4926168.

40. López-Morales CA, Miranda-Hernández MP, Juárez-Bayardo LC, et al. Physicochemical and biological characterization of a biosimilar trastuzumab. Biomed Res Int. 2015;2015:427235. doi: 10.1155/2015/427235.

41. Lee J, Kang HA, Bae JS, et al. Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses. MAbs. 2018 May/Jun;10(4):547-571. doi: 10.1080/19420862.2018.1440170.

42. Solá RJ, Griebenow K. Effects of Glycosylation on the Stability of Protein Pharmaceuticals. J Pharm Sci. 2009 Apr; 98(4): 1223–1245. doi: 10.1002/jps.21504

43. Duivelshof BL, Jiskoot W, Beck A, et al. Glycosylation of biosimilars: Recent advances in analytical characterization and clinical implications. Anal Chim Acta. 2019 Dec 16;1089:1-18. doi: 10.1016/j.aca.2019.08.044.

44. Li H, d'Anjou M. Pharmacological significance of glycosylation in therapeutic proteins. Curr Opin Biotechnol. 2009;20(6):678-84. doi: 10.1016/j.copbio.2009.10.009.

45. Costa AR, Rodrigues ME, Henriques M, et al. Glycosylation: impact, control and improvement during therapeutic protein production. Crit Rev Biotechnol. 2014;34(4):281-299. doi: 10.3109/07388551.2013.793649.

46. ICH Q6B 1999. International conference on harmonisation; guidance on specifications: test procedures and acceptance criteria for biotechnological/biological products. Notice. Food and Drug Administration, HHS. Fed. Regist. 1999;64:44928–44935.

47. ICH Q5E 2004. International conference on harmonisation; guidance on Q5E comparability of biotechnological/biological products subject to changes in their manufacturing process; availability. Notice. Fed. Regist. 2005;70:37861–37862.

48. Zimmermann K, Fido M, Roucka M. Glycosylation Pattern of Biotechnologically Produced Proteins - Lectin Array Technology as a Versatile Tool for Screening? Med Res Arch. March 2018; 6 (3), doi:

49. Hirabayashi J, Kuno A, Tateno H. Development and Applications of the Lectin Microarray. Top Curr Chem. 2015;367:105-24. doi: 10.1007/128_2014_612.

50. Zhang L, Luo S, Zhang B. The use of lectin microarray for assessing glycosylation of therapeutic proteins. MAbs. 2016;8(3):524-535. doi: 10.1080/19420862.2016.1149662.

51. Sarpatwari A, Barenie R, Curfman G, et al. The US Biosimilar Market: Stunted Growth and Possible Reforms. Clin Pharmacol Ther. 2019 Jan;105(1):92-100. doi: 10.1002/cpt.1285.

52. Mulcahy AW, Hlavka JP, Case SR. Biosimilar Cost Savings in the United States: Initial Experience and Future Potential. Rand Health Q. 2018 Mar 30;7(4):3. eCollection 2018 Mar.

53. Leonard E, Wascovich M, Oskouei S, et al. Factors Affecting Health Care Provider Knowledge and Acceptance of Biosimilar Medicines: A Systematic Review. J Manag Care Spec Pharm. 2019 Jan;25(1):102-112. doi: 10.18553/jmcp.2019.25.1.102.

54. Rémuzat C, Kapuśniak A, Caban A, et al. Supply-side and demand-side policies for biosimilars: an overview in 10 European member states. J Mark Access Health Policy. 2017 Apr 28;5(1):1307315. doi: 10.1080/20016689.2017.1307315. eCollection 2017.

55. Tsai WC. Update on Biosimilars in Asia. Curr Rheumatol Rep. 2017 Aug;19(8):47. doi: 10.1007/s11926-017-0677-1.

56. Lim H, Lee SH, Lee HT, et al. Structural Biology of the TNFα Antagonists Used in the Treatment of Rheumatoid Arthritis. Int J Mol Sci. 2018 Mar 7;19(3). pii: E768. doi: 10.3390/ijms19030768.

57. Bellinvia S, Cummings JRF, Ardern-Jones MR, Edwards CJ. Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence. BioDrugs. 2019 Jun;33(3):241-253. doi: 10.1007/s40259-019-00355-4.

58. Liu J, Eris T, Li C, et al. Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab. BioDrugs. 2016 Aug;30(4):321-338. doi: 10.1007/s40259-016-0184-3.

59. Sivendran R, Ramírez J, Ramchandani M, Liu J. Scientific and statistical considerations in evaluating the analytical similarity of ABP 501 to adalimumab. Immunotherapy. 2018 Aug;10(11):1011-1021. doi: 10.2217/imt-2018-0040.

60. Lee N, Lee JJ, Yang H, et al. Evaluation of similar quality attribute characteristics in SB5 and reference product of adalimumab. MAbs. 2019 Jan;11(1):129-144. doi: 10.1080/19420862.2018.1530920.

61. Magnenat L, Palmese A, Fremaux C, et al. Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®. MAbs. 2017 Jan;9(1):127-139. doi: 10.1080/19420862.2016.1259046.

62. Bandyopadhyay S, Mahajan M, Mehta T, et al. Physicochemical and functional characterization of a biosimilar adalimumab ZRC-3197. Dove Press - Biosimilars. December 2014; 2015;5: 1-18. doi:

63. Loizzi V, Del Vecchio V, Gargano G, et al. Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer. Int J Mol Sci. 2017 Sep 14;18(9). pii: E1967. doi: 10.3390/ijms18091967.

64. de Groot AF, Appelman-Dijkstra NM, van der Burg SH, Kroep JR. The anti-tumor effect of RANKL inhibition in malignant solid tumors - A systematic review. Cancer Treat Rev. 2018 Jan;62:18-28. doi: 10.1016/j.ctrv.2017.10.010.

65. Polyzos SA, Makras P, Tournis S, Anastasilakis AD. Off-label uses of denosumab in metabolic bone diseases. Bone. 2019 Aug 24;129:115048. doi: 10.1016/j.bone.2019.115048.

66. Bae SC, Lee YH. Comparative efficacy and safety of biosimilar-infliximab and originator-infliximab in combination with methotrexate in patients with active rheumatoid arthritis: a meta-analysis of randomized controlled trials. Int J Rheum Dis. 2018 May;21(5):922-929. doi: 10.1111/1756-185X.13305.

67. Zrubka Z, Gulácsi L, Brodszky V, et al. Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis. Expert Rev Pharmacoecon Outcomes Res. 2019 Oct;19(5):537-549. doi: 10.1080/14737167.2019.1647104.

68. Koppolu V, Rekha Vasigala VK. Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma. J Cancer Res Ther. 2018 Oct-Dec;14(6):1167-1175. doi: 10.4103/jcrt.JCRT_1290_16.

69. Simeone E, Grimaldi AM, Festino L, et al. Nivolumab for the treatment of small cell lung cancer. Expert Rev Respir Med. 2019 Oct 17. doi: 10.1080/17476348.2020.1681977.

70. Ancau M, Berthele A, Hemmer B. CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date. Expert Opin Biol Ther. 2019 Aug;19(8):829-843. doi: 10.1080/14712598.2019.1611778.

71. Kaegi C, Wuest B, Schreiner J, et al. Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders. Front Immunol. 2019 Sep 6;10:1990. doi: 10.3389/fimmu.2019.01990. eCollection 2019.

72. Elster N, Collins DM, Toomey S, et al. HER2-family signalling mechanisms, clinical implications and targeting in breast cancer. Breast Cancer Res Treat. 2015 Jan;149(1):5-15. doi: 10.1007/s10549-014-3250-x.

73. Mazzotta M, Krasniqi E, Barchiesi G, et al. Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer. J Clin Med. 2019 Feb 18;8(2). pii: E254. doi: 10.3390/jcm8020254.

74. Macaluso FS, Orlando A, Cottone M. Anti-interleukin-12 and anti-interleukin-23 agents in Crohn's disease. Expert Opin Biol Ther. 2019 Feb;19(2):89-98. doi: 10.1080/14712598.2019.1561850.

75. Dobbin-Sears I, Roberts J, O'Rielly DD, Rahman P. Ustekinumab in psoriatic arthritis and related phenotypes. Ther Adv Chronic Dis. 2018 Jun 13;9(10):191-198. doi: 10.1177/2040622318781760.

76. Bonelli M, Scheinecker C. How does abatacept really work in rheumatoid arthritis? Curr Opin Rheumatol. 2018 May;30(3):295-300. doi: 10.1097/BOR.0000000000000491.

77. Pombo-Suarez M, Gomez-Reino JJ. Abatacept for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2019 Apr;15(4):319-326. doi: 10.1080/1744666X.2019.1579642.

78. Papadopoulos Z. Aflibercept: A review of its effect on the treatment of exudative age-related macular degeneration. Eur J Ophthalmol. 2019 Jul;29(4):368-378. doi: 10.1177/1120672119832432.

79. Zhao S, Mysler E, Moots RJ. Etanercept for the treatment of rheumatoid arthritis. Immunotherapy. 2018 Mar 1;10(6):433-445. doi: 10.2217/imt-2017-0155.

80. Cases A. Darbepoetin alfa: a novel erythropoiesis-stimulating protein. Drugs Today (Barc). 2003 Jul;39(7):477-495.

81. Palmer SC, Saglimbene V, Craig JC, et al. Darbepoetin for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2014 Mar 31;(3):CD009297. doi: 10.1002/14651858.CD009297.pub2.

82. Mbanya JC, Sandow J, Landgraf W, Owens DR. Recombinant Human Insulin in Global Diabetes Management - Focus on Clinical Efficacy. Eur Endocrinol. 2017 Apr;13(1):21-25. doi: 10.17925/EE.2017.13.01.21.

83. Clerico M, Contessa G, Durelli L. Interferon-beta1a for the treatment of multiple sclerosis. Expert Opin Biol Ther. 2007 Apr;7(4):535-542.

84. Kroschinsky F, Hölig K, Ehninger G. The role of pegfilgrastim in mobilization of hematopoietic stem cells. Transfus Apher Sci. 2008 Jun;38(3):237-244. doi: 10.1016/j.transci.2008.04.007.

85. Renwick W, Pettengell R, Green M. Use of filgrastim and pegfilgrastim to support delivery of chemotherapy: twenty years of clinical experience. BioDrugs. 2009;23(3):175-186. doi: 10.2165/00063030-200923030-00004.

86. Wojda SJ, Donahue SW. Parathyroid hormone for bone regeneration. J Orthop Res. 2018 Oct;36(10):2586-2594. doi: 10.1002/jor.24075.

87. Morimoto H, Ito Y, Yoden E, et al. Non-clinical evaluation of JR-051 as a biosimilar to agalsidase beta for the treatment of Fabry disease. Mol Genet Metab. 2018 Sep;125(1-2):153-160. doi: 10.1016/j.ymgme.2018.07.009.

88. Revel-Vilk S, Szer J, Mehta A, Zimran A. How we manage Gaucher Disease in the era of choices. Br J Haematol. 2018 Aug;182(4):467-480. doi: 10.1111/bjh.15402.

89. Choi JH, Lee BH, Ko JM, et al. A phase 2 multi-center, open-label, switch-over trial to evaluate the safety and efficacy of Abcertin® in patients with type 1 Gaucher disease. J Korean Med Sci. 2015 Apr;30(4):378-384. doi: 10.3346/jkms.2015.30.4.378.

90. Thomas AE. Haemophilia -The Official Journal of the World Federation of Hemophilia. Volume 24, Issue 1, January 2018, Biosimilars and haemophilia, 17-20.

91. Gholamreza T, Abolghasemi H, Eshghi P, et al. Evaluation of Aryoseven Safety (Recombinant Activated Factor VII) in Patients with Bleeding Disorders (An Observational Post-Marketing Surveillance Study). Iran J Pathol. 2016 Summer; 11(3):204–209.